Harvard Bioscience Q4 2025 net loss was USD 2.8 million as revenue fell 5% to USD 23.7 million

Reuters03-12

Harvard Bioscience Q4 2025 net loss was USD 2.8 million as revenue fell 5% to USD 23.7 million

Harvard Bioscience reported Q4 2025 revenue of USD 23.7 million, down 5%, and gross margin of 59.7%, up 3 percentage points, mainly due to cost containment actions and favorable product mix. Q4 2025 net loss was USD 2.8 million and adjusted EBITDA was USD 3.8 million. For FY 2025, revenue was USD 86.6 million, down 8%, with the decline attributed to a challenging global market and reduced spending by CROs, distributors and academic research institutions. FY 2025 net loss was USD 56.7 million, reflecting a USD 48 million goodwill impairment, while adjusted EBITDA was USD 8.1 million. The company said interim CFO Mark Frost was appointed CFO on a permanent basis and it introduced FY 2026 guidance reflecting anticipated revenue growth driven by new products for translational science.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-001504), on March 12, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618139414?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 19:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618139414","market":"fut","top_or_hot":-1,"title":"Harvard Bioscience Q4 2025 net loss was USD 2.8 million as revenue fell 5% to USD 23.7 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Harvard Bioscience Q4 2025 net loss was USD 2.8 million as revenue fell 5% to USD 23.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harvard Bioscience reported Q4 2025 revenue of USD 23.7 million, down 5%, and gross margin of 59.7%, up 3 percentage points, mainly due to cost containment actions and favorable product mix. Q4 2025 net loss was USD 2.8 million and adjusted EBITDA was USD 3.8 million. For FY 2025, revenue was USD 86.6 million, down 8%, with the decline attributed to a challenging global market and reduced spending by CROs, distributors and academic research institutions. FY 2025 net loss was USD 56.7 million, reflecting a USD 48 million goodwill impairment, while adjusted EBITDA was USD 8.1 million. The company said interim CFO Mark Frost was appointed CFO on a permanent basis and it introduced FY 2026 guidance reflecting anticipated revenue growth driven by new products for translational science.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-001504), on March 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard Bioscience Q4 2025 net loss was USD 2.8 million as revenue fell 5% to USD 23.7 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard Bioscience Q4 2025 net loss was USD 2.8 million as revenue fell 5% to USD 23.7 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-12 19:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Harvard Bioscience Q4 2025 net loss was USD 2.8 million as revenue fell 5% to USD 23.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Harvard Bioscience reported Q4 2025 revenue of USD 23.7 million, down 5%, and gross margin of 59.7%, up 3 percentage points, mainly due to cost containment actions and favorable product mix. Q4 2025 net loss was USD 2.8 million and adjusted EBITDA was USD 3.8 million. For FY 2025, revenue was USD 86.6 million, down 8%, with the decline attributed to a challenging global market and reduced spending by CROs, distributors and academic research institutions. FY 2025 net loss was USD 56.7 million, reflecting a USD 48 million goodwill impairment, while adjusted EBITDA was USD 8.1 million. The company said interim CFO Mark Frost was appointed CFO on a permanent basis and it introduced FY 2026 guidance reflecting anticipated revenue growth driven by new products for translational science.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-001504), on March 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL65X35w:1","article_id":"2618139414","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618139414","pubTimestamp":1773315129,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Harvard Bioscience reported Q4 2025 revenue of USD 23.7 million, down 5%, and gross margin of 59.7%, up 3 percentage points, mainly due to cost containment actions and favorable product mix. Q4 2025 net loss was USD 2.8 million and adjusted EBITDA was USD 3.8 million. For FY 2025, revenue was USD 86.6 million, down 8%, with the decline attributed to a challenging global market and reduced spending by CROs, distributors and academic research institutions. FY 2025 net loss was USD 56.7 million, reflecting a USD 48 million goodwill impairment, while adjusted EBITDA was USD 8.1 million. The company said interim CFO Mark Frost was appointed CFO on a permanent basis and it introduced FY 2026 guidance reflecting anticipated revenue growth driven by new products for translational science.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","HBIO":"哈佛生物科学"},"translate_title":"哈佛生物科学2025年第四季度净亏损280万美元，收入下降5%至2370万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HBIO":0.9},"content_text":"Harvard Bioscience Q4 2025 net loss was USD 2.8 million as revenue fell 5% to USD 23.7 million\n    \n\n        Harvard Bioscience reported Q4 2025 revenue of USD 23.7 million, down 5%, and gross margin of 59.7%, up 3 percentage points, mainly due to cost containment actions and favorable product mix. Q4 2025 net loss was USD 2.8 million and adjusted EBITDA was USD 3.8 million. For FY 2025, revenue was USD 86.6 million, down 8%, with the decline attributed to a challenging global market and reduced spending by CROs, distributors and academic research institutions. FY 2025 net loss was USD 56.7 million, reflecting a USD 48 million goodwill impairment, while adjusted EBITDA was USD 8.1 million. The company said interim CFO Mark Frost was appointed CFO on a permanent basis and it introduced FY 2026 guidance reflecting anticipated revenue growth driven by new products for translational science.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-001504), on March 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618139414","isCrawlerRequest":true}